NCT06945419

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 216 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Conditions

• Healthy
• Overweight
• Obesity
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	LY4086940	Administered orally
DRUG	Placebo	Administered orally
DRUG	LY4086940	Administered IV

Timeline

• Start date: 2025-04-23
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2025-04-25
• Last updated: 2026-04-17

Locations

6 sites across 2 countries: United States, Singapore

Regulatory

• FDA-regulated drug study